RESPIRATORY SYNCYTIAL VIRUS (RSV)
Clinical trials for RESPIRATORY SYNCYTIAL VIRUS (RSV) explained in plain language.
Never miss a new study
Get alerted when new RESPIRATORY SYNCYTIAL VIRUS (RSV) trials appear
Sign up with your email to follow new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Major trial launches for RSV vaccine to protect seniors
⭐️ VACCINE ⭐️ Recruiting nowThis study tests a new RSV vaccine in 25,000 adults aged 60 and older. The goal is to see if a single shot can prevent serious lung infections caused by RSV. Researchers will also check for side effects and measure the body's immune response.
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Phase: PHASE3 • Sponsor: MAXVAX Biotechnology Limited Liability Company • Aim: ⭐️ VACCINE ⭐️
Last updated May 26, 2026 03:53 UTC
-
New RSV vaccine candidate enters human safety testing
⭐️ VACCINE ⭐️ Recruiting nowThis early-stage study is testing a new vaccine called SIBP-A16 to see if it is safe and how the body processes it. The trial involves 140 healthy adults aged 18 to 45. Researchers will monitor for side effects and measure how the vaccine behaves in the body. This is a first step…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Phase: EARLY_PHASE1 • Sponsor: Shanghai Institute Of Biological Products • Aim: ⭐️ VACCINE ⭐️
Last updated May 26, 2026 03:49 UTC
-
New vaccines against RSV and bird flu enter human testing
⭐️ VACCINE ⭐️ Recruiting nowThis early-stage study tests the safety and immune response of experimental vaccines for respiratory syncytial virus (RSV) and a type of bird flu (H5N1) in 570 healthy adults aged 18 to 49. Participants will receive one or two shots, and researchers will monitor side effects and …
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Phase: PHASE1 • Sponsor: Sanofi • Aim: ⭐️ VACCINE ⭐️
Last updated May 26, 2026 03:38 UTC
-
New RSV vaccine trial aims to protect vulnerable patients
⭐️ VACCINE ⭐️ Recruiting nowThis study tests the RSV vaccine Arexvy in 170 adults with weakened immune systems to see if one or two doses work better. Participants will receive three vaccine doses over a year and be monitored for side effects and immune response. The goal is to find the best way to protect …
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Phase: PHASE2 • Sponsor: Johns Hopkins University • Aim: ⭐️ VACCINE ⭐️
Last updated May 22, 2026 13:53 UTC
-
New study aims to protect vulnerable infants from dangerous RSV
Prevention Recruiting nowThis study is checking how safe palivizumab is for preventing severe RSV in infants and young children who are at high risk. About 138 children under 24 months old will receive a monthly injection for up to 5 months. The goal is to track any side effects and ensure the medicine i…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Phase: NA • Sponsor: AstraZeneca • Aim: Prevention
Last updated May 20, 2026 11:53 UTC
-
Massive health survey aims to uncover hidden disease threats in cambodia
Knowledge-focused Recruiting nowThis study will test 10,000 people in Cambodia for antibodies against 57 different infectious diseases, including dengue, flu, and malaria. The goal is to learn how these diseases spread in communities and which ones are most common. This information will help health officials de…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Sponsor: Institut Pasteur du Cambodge • Aim: Knowledge-focused
Last updated May 26, 2026 03:43 UTC